

IAPZOROSCIEGAZIO ZS MAR 2006

	_				Complete if Known
Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	Unassigned F 1 B B			
		niec		Filing Date	Herewith 2 4 5
				First Named Inventor	Salomon et al.
SIA	TEMPERATE	A WIS		Group Art Unit	N/A 1634
	(Use as many shee	ts as nec	essary)	Examiner Name	NA Pohnert
	(**************************************			Attorney Docket Number	251206
Sheet	1	of	3	Client Reference No.	E-075-2003/0-US-03

				U.S. PATENT DOCUMENTS		
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
/SP/	AA	5,256,643		Persico et al.	Oct. 26, 1993	
111	AB	5,654,140		Persico et al.	Aug. 5, 1997	
V	AC	5,792,616		Persico et al.	Aug. 11, 1998	

					GN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*
/SP/	AD	wo	00/06723	A1	Yeda Research and Development Company Ltd. at The Weizmann Institute of Science	Feb. 10, 2000		
	ΑE	wo	02/16413	A2	SmithKline Beecham Biologicals . S.A.	Feb. 28, 2002		
	AF	WO	02/22808	A2	Biogen, Inc.	Mar. 21, 2002		
	AG	wo	02/059620	A2	Government of the U.S. of America, represented by Secretary Dep. of Health and Human Services	Aug. 1, 2002		
	AH	wo	02/077033	A1	Austin Research Institute	Oct. 3, 2002	·	
	AI	wo	02/088170	A2	Biogen, Inc.	Nov. 7, 2002		
1/	AJ	wo	2004/053084	A2	McLean Hospital Corporation	Jun. 24, 2004		
	AK	wo	2004/083375	A2		Sep. 30, 2004		

	•	OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Doc. No.				Translation	
		(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*1	
/SP/	AL				
1	AM	ACKRILL et al., Nucleic Acids Res., 19, 591-598 (1991)			
	AN	ADAMSON et al., J. Cellular Physiology, 190 (3), 267-278 (2002)			
	AO	ADKINS et al., <i>J. Clin. Invest.</i> , 112, 575-587 (2003)			
	AP	BERMAN et al., Mol. Chem. Neuropathol., 34, 25-38 (1998)			
	AQ	BERMAN et al., Neurobiol Dis. 6: 486-498 (1999)			
	AR	BIANCO et al., Cancer Res., 63, 1192-1197 (2003)			
	AS	BIANCO et al., <i>J. Biol. Chem.</i> , 274, 8624-8629 (1999)			
	AT	BIANCO et al., J. Cell. Physiology, 190(1), 74-82 (2002)			
A	A·U	BIANCO et al., Mol. Cell. Bio., 22, 2586-2597 (2002)			
	AV	COLAS et al., Gene, 255, 205-217 (2000)			
	AW	CONCHA et al., Neuron., 28, 399-409 (2000)			
\sqrt{I}	AX	CORASANITI et al., Biochem. Pharmacol., 56, 153-156 (1998)			
V	AY	DATABASE EMBL Online, M96955			

Date Considered Examiner Signature /Steven Pohnert/ (11/06/2007)

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->
--

Please type a plus sign (+) inside this box ->				ADDRESS CONTROL 29 MAR 2006			
				Complete if Known			
Substitute for fo	inside this box institute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Sheet 2 of 3		Application Number	Unassigned			
INIE	DRAKTION	DIEC	I OSLIDE	Filing Date	Hefeville 1571645		
				First Named Inventor	Salemon et al.		
SIA	IEMENI B	r AP	PLICANI	Group Art Unit	NA 1634		
	(Use as many sheet	s as ne	cessary)	Examiner Name	N/A Pohnert		
Sheet	2	of	3	Attorney Docket Number	251206		

Examiner	Doc.	The magazing igumal construmencium catalog etc.) date page(c) volume-iccue gumbet (c) gublichet city.				
Initials	No.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*1		
/SP/	AZ	D'AVERSA et al., Am. J. Pathol., 160, 559-567 (2002)				
1	ВА	DECHIARA et al., Cell, 83, 313-322 (1995)				
	вв	DE LA CRUZ et al., Hum. Genet., 110, 422 428 (2002),				
	BC	DING et al., Nature, 395, 702-707 (1998)				
	BD	DONO et al., Development, 118, 1157-1168 (1993)				
	BE	DUBERLEY et al., Neurosci. Lett., 218, 188-192 (1996)				
	BF	EBERT et al., Exp. Cell Res., 257, 223-229 (2000)				
	BG	ELSON et al., Nat. Neurosci., 3, 867-872 (2000)				
	вн	FRIEDMAN et al., Cell, 38, 745-755 (1984)				
	ВІ	GenBank Accession No. AAA61134				
·	ВJ	GenBank Accession No. M96955				
	вк	GenBank Accession No. X14253				
	BL	GONATAS et al., Brain Res., 855, 23-31 (2000)				
	ВМ	GRANDVAUX et al., Curr. Opin. Infect. Dis., 15, 259-267 (2002)	T.			
	BN	GRITSMAN et al., Cell, 97, 121-132 (1999)				
	во	JOAG et al., J. Virol., 70, 3189-3197 (1996)				
_	BP	JOHNSON et al., Dev. Dyn., 201, 216-226 (1994)				
	BQ	KAWANO et al., Histochem Cell Biol., 17(5),381-9 (2002)	 			
	BR	KINOSHITA et al., Cell, 83, 621-630 (1995)	 	· · · · ·		
	BS	LIU et al., Virology, 260, 295-307 (1999)	 	1		
	BT	LUCIW et al., Virology, 263, 112-127 (1999)	 			
	BU.	MCCORMICK et al., Virology, 272, 112-126 (2000)	 			
	BV	NATH et al., <i>J. Biol. Chem.</i> , 274, 17098-17102 (1999)	 			
	BW	NAVIA et al., <i>Ann. Neurol.</i> , 19, 525-535 (1986)	1			
	BX	NEBULONI et al., <i>J. Neurovirol.</i> , <i>6</i> , 46-50 (2000)	 	 		
	BY	NIEMEYER et al., Cell. Death Differ., 5, 440-449 (1998)	 			
	BZ	NIEMEYER et al., Int. J. Cancer, 81, 588-591 (1999)	t	 		
-	CA	OLIVEIRA et al., J. Comp. Neurol., 447, 381-393 (2002)	 	 		
	CB	PENKOWA et al., Glia, 32, 271-285 (2000)	 	\vdash		
	CC	PETITO, Ann. Neurol. Suppl., S54-S57 (1998)	 	\vdash		
	CD	PLUN-FAVREAU et al., <i>EMBO J.</i> , 20, 1692-1703 (2001)	ł			
	CE	POZZOLI et al., <i>J. Neuroimmunol.</i> , 118, 268-276 (2001)	 	\vdash		
	CF	PRICE et al., Science, 239, 586-592 (1988)	-	 		
		QI et al., Br. J. Cancer, 69, 903-910 (1994)	+-	 		
	CG	RAGHAVAN et al., <i>Brain Pathol.</i> , 7, 851-861 (1997)	┼	 		
	CH		 	├		
	C1	RAGHAVAN et al., Neuropathol. Appl. Neurobiol., 25, 285-294 (1999)				
	Cl	RAPPAPORT et al., J. Leuk. Biol., 65, 458-465 (1999)	├─-	1		
	СК	RAUSCH et al., <i>J. Neuropathol. Exp. Neurol.</i> , 53, 165-175 (1994) REUL et al., <i>Curr. Opin. Pharmacol.</i> , 2, 23-33 (2002)	 	 		

Examiner Signature	/Steven Pohnert/ (11/06/2007)	Date Considered	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->	IAPAR PORTE	TOTOTO SA LIND PANE
	と と (日の)の(ない)	Complete if Known
Substitute for form 1449A/B/PTO	Application Number	Unassigned
INFORMATION DISCLOSURE	Filing Date	Herewith (3/ /3/4) 049
	First Named Inventor	Salomon et al.
STATEMENT BY APPLICANT	Group Art Unit	N/A-1/34

Examiner Name

Attorney Docket Number

		OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,	Trans	slation
Examiner initials	Doc. No.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*
/SP/	СМ	SAKURAI et al., Acta Neuropathol. (Berl), 100, 270-274 (2000)		
-101-1	CN	SALOMON et al., Endocrine-Related Can., 7, 199-226 (2000)		
	CO	SANCHEZ et al., J. Comp. Neurol., 408, 365-377 (1999)		
	CP	SENALDI et al., J. Immunol., 168, 5690-5698 (2002)		
	CQ	SHEN et al., Development, 124, 429-442 (1997)		
	CR	SHIBATA et al., J. Infect. Dis., 176, 362-373 (1997)		
	CS	SINGH et al., Virology, 296, 39-51 (2002)		
	СТ	SWARTZ et al., Brain Res., 896, 86-95 (2001)		
	Cυ	TOULMOND et al., Neurosci Lett., 144, 49-52 (1992)		
	CV	VITKOVIC, Curr. Top. Microbiol. Immunol., 202, 105-116 (1995)		
	cw	WALKER et al., Brain Research, 926 (1-2), 69-79 (2002)		
	СХ	WECHSELBERGER et al., Exp. Cell. Res., 266, 95-105 (2001)		
	CY	WESSELINGH et al. Adv. Neuroimmunol., 4, 199-206 (1994)		
	CZ	WESSELINGH et al., Curr. Opin. Neural., 14, 375-379 (2001)		
	DA	WESSELINGH et al., J. Neuroimmunol., 74, 1-8 (1997)		
	DB	XU et al., Development, 126, 483-494 (1999)		
	DC	ZHANG et al., Cell, 92, 241-251 (1998)		
-	DD	ZIDOVETZKI et al., AIDS Res. Hum. Retro., 14, 825-833 (1998)		
	DE	ZINK et al., J. Virol., 73, 10480-10488 (1999)		
V	DF	ZOCHER et al., J. Neurovirol., 6, 462-477 (2000)		
				
				↓

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

/Steven Pohnert/ (11/06/2007)

(Use as many sheets as necessary)

Sheet

Examiner Signature

Date Considered

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).